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The human sleep-wake cycle is governed by two major factors: a homeostatic hourglass 
process (process S), which rises linearly during the day, and a circadian process C, 
which determines the timing of sleep in a ~24-h rhythm in accordance to the external 
light–dark (LD) cycle. While both individual processes are fairly well characterized, the 
exact nature of their interaction remains unclear. The circadian rhythm is generated by 
the suprachiasmatic nucleus (“master clock”) of the anterior hypothalamus, through 
cell-autonomous feedback loops of DNA transcription and translation. While the phase 
length (tau) of the cycle is relatively stable and genetically determined, the phase of 
the clock is reset by external stimuli (“zeitgebers”), the most important being the LD 
cycle. Misalignments of the internal rhythm with the LD cycle can lead to various somatic 
complaints and to the development of circadian rhythm sleep disorders (CRSD). Non-
24-hour sleep-wake disorders (N24HSWD) is a CRSD affecting up to 50% of totally blind 
patients and characterized by the inability to maintain a stable entrainment of the typi-
cally long circadian rhythm (tau > 24.5 h) to the LD cycle. The disease is rare in sighted 
individuals and the pathophysiology less well understood. Here, we present the case 
of a 40-year-old sighted male, who developed a misalignment of the internal clock with 
the external LD cycle following the treatment for Hodgkin’s lymphoma (ABVD regimen, 
four cycles and AVD regimen, four cycles). A thorough clinical assessment, including 
actigraphy, melatonin profiles and polysomnography led to the diagnosis of non-24-hour 
sleep-wake disorders (N24HSWD) with a free-running rhythm of tau = 25.27 h. A ther-
apeutic intervention with bright light therapy (30 min, 10,000  lux) in the morning and 
melatonin administration (0.5–0.75 mg) in the evening failed to entrain the free-running 
rhythm, although a longer treatment duration and more intense therapy might have been 
successful. The sudden onset and close timely connection led us to hypothesize that 
the chemotherapy might have caused a mutation of the molecular clock components 
leading to the observed elongation of the circadian period.
Keywords: non-24-hour sleep-wake disorder, circadian rhythm sleep disorders, bright light therapy, melatonin, 
Hodgkin’s lymphoma
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INtRoDUCtIoN
In summer 2012, a 40-year-old sighted male patient was referred 
to our center, because of a suspected misalignment between 
his biological clock and the external light–dark (LD) cycle. He 
reported to suffer from daily lapses of sleep on- and offset with 
a self-calculated free-running circadian rhythm of more than 
25  h. The trained electro-engineer presented with an unusual 
set of circumstances preceding the onset of the symptoms: in 
2009, he was diagnosed with Hodgkin’s lymphoma (Stage IVA). 
He was treated with a standardized regimen of multiple courses 
of polychemotherapy (ABVD regimen: adriamycin 50  mg/
bleomycin 20 mg/vinblastine 10 mg/dacarbazine 750 mg; four 
cycles ABVD, four cycles AVD). Luckily, the patient responded 
well and is still in full remission. However, during the oncologi-
cal treatment, he progressively began suffering from tiredness 
and inattentiveness during the day and noticed a gradual shift 
of his sleep-wake rhythm to later hours. After completing the 
treatment, he remained unemployed and could therefore freely 
organize his daily schedule according to his preferred activity 
and sleeping times, which he managed to do using a calendar 
app on his smartphone. At the time of the consultation, he had 
experienced a free-running rhythm for more than 3 years, did 
not suffer from any social disability arising from the symptoms, 
and reported physical and psychological wellbeing, apart from 
a difficulty in concentrating and a lack of attention during 
wakefulness.
Subjective measures of the patient’s daytime sleepiness were 
assessed using the Epworth Sleepiness Scale (ESS) (1) and the 
Pittsburgh Sleep Quality Index (PSQI) (2), which both did not 
show any pathological findings (ESS = 0/24, PSQI daytime sleepi-
ness – subscore = 2/3). In particular, the ESS score was 0 of 24 
points (pathological > 10 points); however, the patient remarked 
to actually experience fatigue with inattentiveness and lack of 
concentration, rather than actual daytime sleepiness.
To quantify the described symptoms, we conducted multiple 
standard tests used for the assessment of circadian sleep-wake 
disorders, including non-dominant wrist actigraphy record-
ings with activity storage in 1-min intervals over 5  months 
(Actiwatch, Cambridge Neurotechnology Ltd., UK), serial 
melatonin measurements in saliva samples collected in 1–3 h 
intervals across 24–48 h (Salivettes, Sarstedt AG, Switzerland; 
direct double-antibody immunoassay, sensitivity of 0.2 pg/ml, 
Bühlmann Laboratories AG, Allschwil/Switzerland), an in-lab 
melatonin suppression test by bright light (Daylight, Uplift 
Technologies, Canada; 10,000 lux measured on eyelevel, 20 cm 
distance to the light source), and polysomnography (PSG; 
Vitaport-3 digital recorder and Vitaport sleep scoring software, 
TEMEC Instruments BV, Kerkrade, Netherlands).
We also analyzed the patient’s circadian rhythm at the molecu-
lar level by measuring the circadian period (tau) of clock gene 
transcription in cultivated fibroblasts isolated from five skin biop-
sies. In this technique, a mouse Bmal1 promoter, which drives the 
expression of a luciferase gene, is introduced into the fibroblasts 
by lentiviral transfection. After synchronization with dexametha-
sone, tau is calculated from the circadian bioluminescence of the 
cell cultures. The in vitro analysis was conducted in every detail as 
described in the work of Pagani and colleagues, to which we refer 
for further information (3).
While the results from the PSG were within the normal range 
(five NREM-REM cycles with slightly increased fragmentation 
due to short wake periods, sleep efficiency =  82% at 9  h time 
in bed, and normal proportions of sleep stages), the actigraphy 
recording showed a free-running sleep-wake rhythm with a phase 
length (tau) of 25.27 h (Figure 1). The melatonin profiles showed 
a similar free-running rhythm, synchronous to the observed 
sleep-wake cycle, however, with a prolonged mean phase angle of 
3.38 ± 2.27 h between melatonin onset and sleep onset. The mela-
tonin suppression test by bright light (10,000 lux, see Figure 2) 
showed a normal response of the physiological LD-mediated 
melatonin release from the pineal gland. The analysis of tau in 
fibroblasts confirmed our in vivo measurement and showed an 
even longer tau in vitro (=25.6 h) than in vivo.
Based on the collected data, we confirmed the diagnosis of 
N24HSWD and decided for a therapeutic approach based on 
melatonin administration (0.5–0.75  mg) in the evening, com-
bined with bright light therapy (10,000  lux for 30  min) in the 
morning.
The combination of melatonin, morning light therapy, and 
regular wake-up times (set with an alarm clock) during the 
first week of treatment led to an apparent stabilization of sleep 
offset in the morning. However, sleep onset still followed the 
original free-running rhythm with consecutive delays every day 
(Figure 1). The profile of melatonin secretion was also unaffected 
by the treatment and remained non-entrained. Unfortunately, the 
patient had to stop taking melatonin after only 4 days because it 
triggered severe headaches.
In summary, the applied therapeutic intervention was 
unable to resynchronize the free-running rhythm of the patient. 
Nevertheless, he decided to continue with morning light therapy 
after getting up, because he experienced improved attentiveness 
and concentration during wakefulness.
BaCKGRoUND – tHe MoLeCULaR 
CLoCK
The ability to anticipate predictable environmental changes and 
adapt behavioral responses to daily or seasonal variations is a 
highly conserved biological program among various species, 
from single cell organisms to more complex life forms, such as 
insects, rodents, birds, and humans (4).
The phenomenon’s underlying principle, a genetically encoded 
“molecular clock,” basically consists of positive and negative 
feedback mechanisms of DNA translation: the dimerization of 
the transcription factor CLOCK with BMAL1/2 or NPAS2 initi-
ates the expression of the clock proteins PERIOD (PER1, PER2, 
and PER3) and CRYPTOCHROME (CRY1 and CRY2), which 
accumulate and inhibit CLOCK:BMAL1/2 (or CLOCK:NPAS2) 
activity, blocking their own expression and therefore closing the 
cycle (5). These molecular loops intrinsically generate a circadian 
rhythm (lat. circa diem = about a day), which is then directly or 
indirectly translated into behaviors, such as locomotion and feed-
ing or sleep-wake cycles, according to environmental settings. 
FIGURe 1 | actigraphy recording over 5 months (august–December 2012). Note the free-running rhythm of activity (black bars) and sleep-periods (lighter 
areas) with a calculated intrinsic period of tau = 25.27 h and a mean phase angle of 3.38 ± 2.27 h between dim light melatonin onset (DLMO) and sleep onset. Red 
spots: DLMO = 3 pg. The patient received 30 min BLT in the morning between October 21, 2012 and December 7, 2012 and oral melatonin in the evening from 
October 21, 2012 to October 24, 2012 (discontinued due to side effects). During the first days of treatment, sleep onset continued to free-run, while sleep offset 
remained relatively stable (for ~10 days).
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While the period length (tau) remains relatively stable, the phase 
is influenced and reset by external cues, with the most important 
“zeitgeber” being the 24-h LD cycle (6).
In mammals, the circadian timing system is organized 
in a hierarchical manner, with the suprachiasmatic nucleus 
(SCN), a formation of 20,000 neurons in the anterior 
FIGURe 3 | Range of the intrinsic period length (based on data presented in Ref. (14); n = 157 healthy individuals). The length of the circadian period 
shows a rather large interindividual variability mimicking a bell distribution centered around 24.15 h (±0.2 h) with extreme taus predisposing to the development of 
certain circadian rhythm disorders (12). However, the range of normal entrainment, as well as pathological alignment, seems to show rather large overlaps in the 
length of tau, indicating the influence of other factors in the determination of chronotypes and the development of circadian rhythm sleep disorders, respectively.
FIGURe 2 | In-lab melatonin suppression test with bright light 
(BL: 10’000 lux). Schedule: the patient rose at 2:45 a.m. (according to his 
free-running rhythm), came to our lab at 10 a.m. and was kept under dim 
light conditions (<8 lux). Saliva samples for melatonin measurement were 
collected hourly from 11:00 a.m. on. DLMO (3 pg threshold, red dashed line) 
occurred at 2:16 p.m. The melatonin suppression test was scheduled from 
4:30 p.m. to 5:39 p.m. with saliva samples in 15 min intervals. BL (yellow 
rectangle) caused a significant reduction of melatonin secretion, indicating a 
normal physiological response via an intact retina–RHT–pineal axis. The 
patient spent the following night in the lab for PSG recording with sleep onset 
at 6:40 p.m. and sleep offset at 3:45 a.m.
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hypothalamus, acting as the “master clock” (7). These clock 
neurons directly receive non-visual light information from 
photoreceptive retinal ganglion cells (RGCs) (6, 8) via the 
retinohypothalamic tract, resetting and synchronizing their 
internal rhythm to the environmental LD cycle (6, 9). This 
self-sustained neuronal oscillator then disseminates the 
integrated circadian information through direct or indirect 
electrical and humoral pathways to “slave oscillators” in 
peripheral tissues, what ultimately leads to the circadian 
expression of behavior (10, 11).
The systems’ plasticity and ability to incorporate external 
information is vital for reacting to changes of the environ-
ment but makes it also vulnerable to non-physiological cues 
introduced by our modern day life, such as the light exposure 
during the evening hours, shift work, or the crossing of multiple 
time zones by transmeridian flights. These conditions can cause 
a misalignment of the internal and external phase, resulting in 
circadian rhythm sleep disorders (CRSD), such as shift work 
sleep disorder (SWSD), advanced sleep phase syndrome (ASPS), 
delayed sleep phase syndrome (DSPS), jet lag (JL), and non-
24-hour  sleep-wake disorder (N24HSWD) (12). The commonal-
ity of CRSD is the general inability to fall asleep or rise at the 
desired time of the day due to asynchrony of the internal clock 
with the external LD cycle, leading to daytime sleepiness with 
lack of  concentration, social dysfunction, and a predisposition 
to various clinical conditions ranging from metabolic disorders 
to cancer (13–15).
NoN-24-HoUR sLeep-WaKe DIsoRDeR
The internal period length (tau – τ) of individuals with normal 
sleep is in average slightly longer than the environmental LD 
cycle (about 24.15 ± 0.2 h, see Figure 3) with a shorter average 
tau in women (24.09 ± 0.2 h) than in men (24.19 ± 0.2 h) (16). 
Daily entrainment of the SCN by light exposure and other phase-
shifting agents ensures the alignment through the shift of the 
internal rhythm.
In N24HSWD the affected individuals typically show an 
intrinsic rhythm longer than 24 h and the inability to maintain 
a stable entrainment to the external LD cycle. This results in a 
daily gradual shift of sleep on- and offset and consequently causes 
the behavioral rhythms to free-run. Therefore, affected patients 
show a cycling, relapsing–remitting pattern of sleep disturbances, 
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with insomnia and/or excessive daytime sleepiness, fatigue, dif-
ficulty concentrating, and memory problems in the symptomatic 
phases, when the internal rhythm is out of sync with the solar 
day, and completely asymptomatic periods (13, 17). The direct 
negative influences on social activities and work obligations 
might contribute to a worsening of the quality of life and to the 
development of psychiatric illnesses, especially affective disor-
ders (13, 17).
Most patients affected by N24HSWD are totally blind indi-
viduals, with an estimated prevalence of ~50% or more in this 
population (13, 18). The average period length of ~24.5 h (range 
23.8–25.1 h) in these subjects shows an overlap with the range 
of tau of normally entrained individuals (12), but the lack of a 
functional pathway of light transmission (depending on the cause 
of the blindness) disables the regulating role of light as “zeitgeber” 
and therefore the entrainment of the circadian pacemaker to the 
24-h day (17).
In contrast, N24HSWD in sighted individuals is a rare condi-
tion with symptom onset in teenage years and preference for the 
male sex (4:1 ratio). Affected individuals often show an extreme 
period length ranging from 24.5 to 25.5 h or more (17), which is 
thought to exceed the capability of entrainment, making it the 
primary risk factor for the development of this disorder. Other 
likely contributing factors are a decreased or heightened response 
of the clock mechanism to light, reduced or untimely environ-
mental or social cues (in about a quarter of patients due to comor-
bid psychiatric disorders), and genetic variation of alleles of the 
molecular clock, although no specific variant has been directly 
linked to N24HSWD yet (17). However, the exact mechanism 
and extend of contribution of each presumed pathophysiological 
aspect remain unclear.
The clinical assessment of individuals with documented sleep 
problems related to an abnormal synchronization between the 
24-h LD cycle and the endogenous circadian rhythm consists of 
at least two consecutive weeks of actigraphy with sleep diaries 
and continuous measurement of the core body temperature 
or serial measurement of melatonin in serum, saliva, or urine 
(ICSD-3) (17, 19).
Once diagnosed, the therapeutic aim is to resynchronize the 
longer than 24 h sleep-wake cycle to the 24-h day by inducing a 
daily shift of the circadian pacemaker.
Although there is insufficient evidence supporting the effec-
tiveness of any treatment option for sighted individuals with 
N24HSWD to date (20), experts suggest the use of bright light 
therapy and/or melatonin administration (21).
In sighted patients, morning bright light should be applied 
when their circadian phase is synchronous to the solar day in 
order to stop a further shift to later hours. Melatonin is given 
in the evening (in blind and sighted individuals) to promote 
sleep onset at proper clock times and avoid a progressive phase 
delay due to the free-running rhythm (21). Furthermore, a new 
melatonin receptor agonist (22), which preferably acts on the 
MT2 receptor (responsible for the phase-shifting abilities of 
melatonin), recently gained EMA approval for the treatment of 
N24HSWD in blind patients (23).
DIsCUssIoN
Over the course of the past decades, several case reports about 
sighted patients suffering from N24HSWD have been published, 
but only a small number refers to patients with symptom onset 
directly related or attributed to external events, the most common 
being head trauma (24, 25). The presented case combines several 
possible triggers of N24HSWD in our patient, each of which 
theoretically may lead to unfavorable light exposure; lacking 
social engagement; new habits concerning sleep, exercise, and 
meal times; and the development of affective disorders.
Sleep-wake regulation is governed by two major processes 
(26, 27) – the homeostatic sleep drive (process S), which linearly 
rises during waking hours, and the circadian rhythm (process 
C), which modulates the timing of sleep  –  and shows a high 
level of interindividual variability. An individual combination of 
different gene polymorphisms directly or indirectly influences 
the involved parameters (see Figure  4), such as the circadian 
rhythm itself (28), the homeostatic sleep drive (29–31), as well 
as the systems’ ability to receive, process, and integrate external 
zeitgebers (32).
As mentioned above, the greatest risk factor for the develop-
ment of “endogenous” CRSD (12) is the length of the circadian 
cycle. However, the relationship between the intrinsic period 
length and the development of CRSD seems to be not that linear 
(see Figure 3). Tau of normally entrained individuals, different 
chronotypes, and patients suffering from CRSD shows significant 
overlaps (34), suggesting additional factors at play.
In this case, the close timely connection between symptom 
onset and the cancer treatment could lead the argument in two 
possible directions: first of all, since the patients’ endogenous cycle 
length prior to the treatment is unknown, it is possible that he 
always had a rather long tau and the loss of a structured daily life 
just uncovered the free-running rhythm. One could even argue 
that the chronic misalignment of his internal tau with the external 
LD cycle in the sense of a “social jet lag” predisposed him to the 
development of the lymphoma in the first place – epidemiologi-
cal studies point to a close relationship between alterations of core 
clock genes as well as chronic circadian misalignment (e.g., by 
shift work) and susceptibility to cancer (14, 15).
On the other hand, the aggressive chemotherapy regimen 
used to treat lymphoma is in 20% of the cases associated with 
the development of secondary cancers caused by specific gene 
mutations (35). Topoisomerase II inhibitors, such as adriamycin, 
are known to cause chromosomal rearrangements involving the 
MLL gene, which encodes histone-modifying enzymes linked to 
transcriptional activation. MLL1, a H3K4-specific methyltrans-
ferase, was shown to directly interact with CLOCK:BMAL1 and 
contribute to its rhythmic recruitment to circadian promotors, 
facilitating circadian gene transcription (36). Another member 
of the family, MLL3, was also shown to play a fundamental role 
in gene transcription of the core clock mechanism itself: mouse 
liver cells containing catalytic inactive MLL3 showed severe 
disruption of PER1/2, CRY1/2, and Bmal1 transcription (37). 
A modification of the MLL gene by the chemotherapy could, 
FIGURe 4 | two-factor model of sleep-wake regulation with interactions and genetic modifiers of the involved factors. Sleep regulation is governed by 
two major factors: the homeostatic process S (a) and the circadian process C (B) (26, 27). However, the exact interaction between these two factors (bold arrows) 
and individual extend of contribution to the sleep-wake regulation remains unclear. Both processes show considerable interindividual differences: the ability to build 
up sleep pressure and therefore vulnerability to sleep loss was shown to depend on gene polymorphism of enzymes involved in dopamine and adenosine 
processing (29, 30) and polymorphisms of the clock gene PER3 (31). The circadian rhythm incorporates two different properties: the bell-distributed, genetically 
determined cycle length tau and the amplitude of the expressed oscillation [e.g., Bmal1 transcription (33), which influences the vulnerability of the system to resetting 
stimuli (yellow arrow)]. Potential further interactions between process S and external zeitgebers are indicated as dotted arrows.
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therefore, potentially have caused a disruption of circadian gene 
transcription, contributing to the observed extreme phenotype.
In general, especially alterations within the negative feedback 
loop seem to modify the cycle length. The fine-tuning mechanism 
extending tau to ~24 h involves the post-translational modifica-
tion of CRY1, CRY 2, PER1, and PER2, regulating their nuclear 
translocation and proteosomal degradation (38–41). Mutations in 
the phosphorylation sites of PER, for example, can either shorten 
or lengthen the cycle dramatically due to altered accessibility of 
the protein to degradation (39). Furthermore, alterations of the 
PER phosphorylases CK1 ϵ and CK1 δ can have a similar effect 
(42–44): a gain of function mutation of CK1 δ, which leads to 
a more effective phosphorylation and hence faster degradation 
of PER, causes familial cases of ASPS (28). Apart from its direct 
mutagenic properties, genotoxic stress in general is also known to 
influence the length of tau: the clock proteins CRY1 and CRY2 are 
ontogenetically derived from DNA repair enzymes and upregu-
lated in response to mutation accumulating in the cells (45). Both 
CRYs are repressors of clock gene transcription and thus lengthen 
and stabilize the intrinsic SCN rhythm (46–48). The more potent 
action of CRY1 in slowing the clock is also attenuated by CRY2, 
demonstrating separate roles of the two proteins within the core 
clock mechanism (48).
The amplitude of circadian oscillation as another discrete 
clock property is associated with the vulnerability of the system 
to resetting stimuli in a directly proportional manner (6, 33). 
A mutation of CLOCK in mice has been shown to dampen the 
amplitude of the circadian oscillation, causing phenotypes to 
exhibit a greater susceptibility to light as a zeitgeber than wild 
type (49). Furthermore, neuropeptides regulating the internal 
synchronization of the SCN neurons and alterations of upstream 
(50, 51) and downstream mechanisms (52) seem to be involved. 
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In humans, the amplitude of the oscillation shows considerable 
interindividual differences as well (33). Accordingly, our patients’ 
reluctance to various and even combined attempts to shift the 
circadian phase could be an expression of a comparably strong 
circadian oscillation, independent of the extreme cycle length 
and thus explaining the observed treatment failure.
Are there other options left to achieve entrainment? First of 
all, headaches caused by melatonin administration are a common 
side effect, which habituate during the course of the treatment 
(53). Therefore, it could be a justified to wait for the headaches to 
subside, especially since some case studies report a delayed treat-
ment response to melatonin (54). Additionally, the use of more 
MT2-selective melatonin receptor agonists (20) could prove 
superior in the phase-shifting abilities compared to melatonin, 
with a theoretically reduced propensity to cause side effects (55, 
56). Second, light therapy was conducted for only 30 min in the 
morning  –  a longer, more intense therapy could have had the 
desired effect, particularly when one assumes that our patient 
expressed a comparatively strong circadian rhythm. Finally, 
based on recent research which points to a greater plasticity of 
the cycle length than previously thought (57), the third possibility 
would be to gradually change the period length in a laboratory 
setting and slowly entrain it to a ~24-h LD cycle.
The exact cause of the N24HSWD in the presented case remains 
hard to pinpoint and subjects to speculation. However, considering 
the physiology of the circadian cycle, the complexity of steps, and the 
influencing factors involved, a single cause seems questionable. The 
conclusion for treatment options in this case and in general must 
therefore be to apply a multimodal therapy concept with a combina-
tion of the above-mentioned strategies adapted to the most likely 
causing factor. Nevertheless, randomized controlled trials studying 
the optimal combination of the established strategies and incorpora-
tion of new therapeutic approaches would be vital to finally establish 
a treatment consensus for N24HSWD in sighted patients.
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